Advertisement.

PCSA Projected Dividend Yield

Com Par $0.0001/Processa Pharmaceuticals Inc ( NASDAQ : PCSA )

Processa Pharmaceuticals is a biopharmaceutical company focused on utilizing the Processa Regulatory Science Approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. Co.'s pipeline consists of three oncology drugs: NGC Capecitabine, which is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase; NGC-Gemcitabine, which is a cytidine analog similar to gemcitabine (Gemzar®), but different enough in chemical structure that some patients are more likely to respond to PCS3117 than gemcitabine; and NGC-Irinotecan, which is an analog of SN38, the active metabolite of irinotecan; and two non-oncology drugs: PCS12852 and PCS499.

21 YEAR PERFORMANCE RESULTS

PCSA Dividend History Detail
PCSA Dividend News
PCSA Competitors News

# of Shares: 0

Closing Price: 0.98

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000